Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1287008

USP

Furosemide

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Sign Into View Organizational & Contract Pricing

Select a Size

200 MG
€401.00

€401.00

In StockDetails

Request a Bulk Order
All Photos(1)

Select a Size

Change View
200 MG
€401.00

About This Item

Empirical Formula (Hill Notation):
C12H11ClN2O5S
CAS Number:
54-31-9
Molecular Weight:
330.74
MDL number:
MFCD00010549
UNSPSC Code:
41116107
PubChem Substance ID:
329749916
NACRES:
NA.24

€401.00

In StockDetails

Request a Bulk Order

grade

pharmaceutical primary standard

API family

furosemide

manufacturer/tradename

USP

mp

220 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

Gene Information

human ... SLC12A1(6557)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Furosemide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Furosemide Injection
  • Furosemide Oral Solution
  • Furosemide Tablets

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

F0700000

Furosemide, European Pharmacopoeia (EP) Reference Standard

F0702000

Furosemide impurity A, European Pharmacopoeia (EP) Reference Standard

1287020

Furosemide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1287030

Furosemide Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001493

Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard

BP547

Furosemide, British Pharmacopoeia (BP) Reference Standard

PHR1816

Furosemide Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP074

4-Chloro-5-sulfamoylanthranilic acid, British Pharmacopoeia (BP) Reference Standard

PHR2457

2,4-dichlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
Adam D DeVore et al.
European journal of heart failure, 17(3), 340-346 (2015-01-27)
Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. We analysed data
Hannah Zacharias et al.
Palliative medicine, 25(6), 658-663 (2011-03-15)
Patients with advanced chronic heart failure (CHF) can experience 'revolving door' admissions, often for parenteral diuretics, when time at home is precious. Home intravenous diuretic services are patchy. This retrospective review describes 43 consecutive episodes of continuous subcutaneous infusion of
Susan B LeGrand et al.
Annals of internal medicine, 149(4), 259-263 (2008-08-20)
Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in
Céline Laurencé et al.
Chemosphere, 113, 193-199 (2014-07-30)
The presence of trace levels of organic contaminants in the environment is currently an environmental concern. When these contaminants are subjected to environmental transformations, environmental transformation products (ETPs) are obtained, whose structures often remain unknown. The absence of information concerning
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service